If you have advanced nonsquamous NSCLC, ask your doctor if a plan that starts with ALIMTA and stays with ALIMTA may be right for you.

ALIMTA can suppress bone marrow function, which may cause low blood cell counts.

Understanding more about your type of lung cancer and your treatment options may seem overwhelming. This site is designed to help you learn more about your condition and play a more active role in your care. The site includes information about ALIMTA® (pemetrexed for injection) therapy for advanced nonsquamous NSCLC and malignant pleural mesothelioma (MPM).

photo - Communication Is Key

Communication
Is Key

Print Questions
photo - How ALIMTA Appears to Work

How ALIMTA Appears to Work

Learn More
photo - Your Guide to ALIMTA

Your Guide to ALIMTA

Download Guides

ALIMTA Indications

ALIMTA is approved by the FDA in combination with cisplatin (another chemotherapy drug) for the initial treatment of advanced nonsquamous non-small cell lung cancer (NSCLC), a specific type of NSCLC. ALIMTA is not indicated for patients who have a different type of NSCLC called squamous cell.

ALIMTA is approved by the FDA for the treatment of patients with advanced nonsquamous non-small cell lung cancer (NSCLC), a specific type of NSCLC, to maintain the effect of initial treatment with chemotherapy and whose disease has not worsened. ALIMTA is not indicated for patients who have a different type of NSCLC called squamous cell.

ALIMTA is approved by the FDA as a single agent (used alone) for the treatment of patients with advanced nonsquamous non-small cell lung cancer (NSCLC), a specific type of NSCLC, after prior chemotherapy. ALIMTA is not indicated for patients who have a different type of NSCLC called squamous cell.

ALIMTA is a treatment for malignant pleural mesothelioma (MPM), which is a cancer that affects the inside lining of the chest cavity. ALIMTA is given with cisplatin, another anticancer medicine (chemotherapy), when surgery is not an option.

ALIMTA can suppress bone marrow function, which may cause low blood cell counts.

Your doctor may choose ALIMTA therapy for you because it has been approved specifically for your type of advanced nonsquamous non-small cell lung cancer.

ALIMTA is not indicated for the treatment of patients with squamous cell non-small cell lung cancer.

If you do not know your lung cancer type, be sure to talk to your healthcare team.

About Non-small Cell Lung Cancer
ALIMTA in Advanced Nonsquamous Non-small Cell Lung Cancer
About Malignant Pleural Mesothelioma
ALIMTA in Malignant Pleural Mesothelioma
Financial Assistance and Patient Resources

ALIMTA Indications

ALIMTA is approved by the FDA in combination with cisplatin (another chemotherapy drug) for the initial treatment of advanced nonsquamous non-small cell lung cancer (NSCLC), a specific type of NSCLC. ALIMTA is not indicated for patients who have a different type of NSCLC called squamous cell.

ALIMTA is approved by the FDA for the treatment of patients with advanced nonsquamous non-small cell lung cancer (NSCLC), a specific type of NSCLC, to maintain the effect of initial treatment with chemotherapy and whose disease has not worsened. ALIMTA is not indicated for patients who have a different type of NSCLC called squamous cell.

ALIMTA is approved by the FDA as a single agent (used alone) for the treatment of patients with advanced nonsquamous non-small cell lung cancer (NSCLC), a specific type of NSCLC, after prior chemotherapy. ALIMTA is not indicated for patients who have a different type of NSCLC called squamous cell.

ALIMTA is a treatment for malignant pleural mesothelioma (MPM), which is a cancer that affects the inside lining of the chest cavity. ALIMTA is given with cisplatin, another anticancer medicine (chemotherapy), when surgery is not an option.

ALIMTA can suppress bone marrow function, which may cause low blood cell counts.